- Home
- HEQ vs VXRT Comparison
HEQ vs VXRT Comparison
Compare HEQ & VXRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HEQ
- VXRT
- Stock Information
- Founded
- HEQ 2011
- VXRT N/A
- Country
- HEQ United States
- VXRT United States
- Employees
- HEQ N/A
- VXRT N/A
- Industry
- HEQ Investment Managers
- VXRT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HEQ Finance
- VXRT Health Care
- Exchange
- HEQ Nasdaq
- VXRT Nasdaq
- Market Cap
- HEQ 119.1M
- VXRT 119.0M
- IPO Year
- HEQ N/A
- VXRT N/A
- Fundamental
- Price
- HEQ $9.98
- VXRT $0.34
- Analyst Decision
- HEQ
- VXRT Strong Buy
- Analyst Count
- HEQ 0
- VXRT 2
- Target Price
- HEQ N/A
- VXRT $3.00
- AVG Volume (30 Days)
- HEQ 43.1K
- VXRT 1.9M
- Earning Date
- HEQ 01-01-0001
- VXRT 05-12-2025
- Dividend Yield
- HEQ 9.78%
- VXRT N/A
- EPS Growth
- HEQ N/A
- VXRT N/A
- EPS
- HEQ N/A
- VXRT N/A
- Revenue
- HEQ N/A
- VXRT $28,700,000.00
- Revenue This Year
- HEQ N/A
- VXRT N/A
- Revenue Next Year
- HEQ N/A
- VXRT N/A
- P/E Ratio
- HEQ N/A
- VXRT N/A
- Revenue Growth
- HEQ N/A
- VXRT 288.94
- 52 Week Low
- HEQ $9.08
- VXRT $0.28
- 52 Week High
- HEQ $11.84
- VXRT $1.07
- Technical
- Relative Strength Index (RSI)
- HEQ 47.41
- VXRT 38.12
- Support Level
- HEQ $9.73
- VXRT $0.31
- Resistance Level
- HEQ $9.99
- VXRT $0.38
- Average True Range (ATR)
- HEQ 0.24
- VXRT 0.04
- MACD
- HEQ 0.02
- VXRT 0.01
- Stochastic Oscillator
- HEQ 60.98
- VXRT 46.08
About HEQ John Hancock Hedged Equity & Income Fund of Beneficial Interest
John Hancock Hedged Equity & Income Fund is a closed-end management investment company. Its investment objective is to provide total return with a focus on current income and gains and also consisting of long-term capital appreciation. It invests in various sectors such as financials, consumer discretionary, information technology, energy, healthcare, materials, real estate, consumer staples, short-term investments, and others.
About VXRT Vaxart Inc
Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases. The products under its tablet pipeline consist of the treatment of Coronavirus, Norovirus, Seasonal Influenza, RSV(respiratory syncytial virus), and HPV(Human papillomavirus) Therapeutic. It operates in a single segment, which is the discovery and development of oral recombinant protein vaccines. Geographically all the business activity functions through the region of the United States.